newsfilter
← Latest News
Business Wire·

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

- Study completion anticipated in mid-2027 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s